Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

JAMA Oncol. 2019 Jan 1;5(1):117-118. doi: 10.1001/jamaoncol.2018.5730.
No abstract available

Publication types

  • Comment

MeSH terms

  • Breast Neoplasms*
  • Chemoradiotherapy
  • Humans
  • Receptor, ErbB-2
  • Trastuzumab

Substances

  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab